CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors, including metastatic triple negative breast cancer and metastatic colorectal cancer, as well as an ongoing Phase 2 trial in graft versus host disease (GvHD) and as an HIV monotherapy.
“Our team is focused on developing leronlimab (PRO140), a monoclonal antibody, to be used as a platform drug for a variety of indications,” Nader Pourhassan, president and CEO, says in an interview with BioTuesdays. “Our molecule offers us very high opportunities in additional disease states.”
Dr. Pourhassan explains that leronlimab (PRO140), which has FDA fast track designation, is a new biologic drug that inhibits the CCR5 co-receptor on the surface of T-cells and has successfully completed nine, Phase 1,2 and 3 clinical trials in more than 800 patients, without any serious adverse events. CCR5 expression has been shown to impact progression of various diseases, including HIV, cancer, GvHD, non-alcoholic steatohepatitis (NASH).
|
|
